Description,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM
DAQRLHYYR,Positive-High,=,1.37,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9709041413266638
EVFEYIIFR,Positive-High,=,4.69,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8571659657125387
MSMEISIHR,Positive-High,=,0.98,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,1.0018672015993737
EFQDFTVPR,Positive-High,=,1.78,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9467074694927152
EFVDLYVPR,Positive-High,=,5.11,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8492391099579246
EVASVWVER,Positive-High,=,11.48,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7744310163538215
EVYDIAFSR,Positive-High,=,1.29,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9764651167815072
MTILQTYFR,Positive-High,=,3.19,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8927869974500149
QTKPVVVYR,Positive-High,=,2.1,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9314276757594562
EVINDYHFR,Positive-High,=,5.33,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8453432968595292
TTTEHRFFR,Positive-High,=,1.99,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9364003013141312
DIYNHRFHR,Positive-High,=,2.4,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9190862590395849
DTYLHRVAR,Positive-High,=,2.19,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9275492045009928
DVFPGPSFR,Positive-High,=,2.18,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9279721953338091
EFFIPRVGR,Positive-High,=,1.47,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9643927638197769
EFFSINAQR,Positive-High,=,0.28,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,1.1176517339220384
ELFDFLHAR,Positive-High,=,1.68,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9520513470999056
ETFNSFLRR,Positive-High,=,2.9,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9015958821885915
ETFPQRHMR,Positive-High,=,3.14,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8942471121086816
ETHFPFAIR,Positive-High,=,2.11,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9309886092061754
ETMPSPYGR,Positive-High,=,3.1,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8954320428985791
ETVERIFRR,Positive-High,=,1.77,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9472281657186604
ETYKYLYGR,Positive-High,=,1.79,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9461896903477632
ETYLHRIGR,Positive-High,=,1.69,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.951502839046985
EVKESPFFR,Positive-High,=,3.63,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8808448182219821
FTWNINHAR,Positive-High,=,3.22,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8919218741070485
FVFDRPVHR,Positive-High,=,0.95,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,1.0047406973635915
MLYGLIHAR,Positive-High,=,3.45,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.885545322788399
MVQNRVFLR,Positive-High,=,1.46,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9650236422805892
NTLQLHRYR,Positive-High,=,3.4,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8868945925273352
NTNDFVTLR,Positive-High,=,4.87,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8536851776920877
QLYPRNFLR,Positive-High,=,3.85,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8754065829387586
STARHLYLR,Positive-High,=,0.92,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,1.0077064064297132
SYIDRLAPR,Positive-High,=,1.43,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.966942534784916
VVAAVRWRR,Positive-High,=,3.64,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8805905585412772
YVFPKPFNR,Positive-High,=,1.43,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.966942534784916
YVQRFHYSR,Positive-High,=,1.37,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,0.9709041413266638
YYYYHRQYR,Positive-High,=,0.98,nM,HLA-A*33:03,I,Literature,2022,Characterization of HLA-A*33:03 epitopes via immunoprecipitation and LC-MS/MS.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),9,1.0018672015993737
KLVVVGAVGV,Positive,=,35810.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.030850523240273375
LLVVGAAGV,Positive,=,17540.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.09681705030808807
LLVVGARGV,Positive,=,23700.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06899845243249825
LLVVGAVGV,Positive,=,25560.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06201553842241093
LLVVVGARGV,Positive-High,=,6550.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1878557861679665
VVGAAGVGK,Positive,=,11230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.13802817372234089
VVGACGVGK,Positive,=,29080.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05009089267048394
VVGASGVGK,Positive,=,12710.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.12658613552185505
VVGAVGVGK,Positive-High,=,5071.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.21150941437613716
VVVGAAGVGK,Positive-High,=,7030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1813194548017949
VVVGACGVGK,Positive,=,15630.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1074727069657454
VVVGADGVGK,Positive,=,15030.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1110905205326742
VVVGARGVGK,Positive,=,46140.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.007425545197936367
VVVGASGVGK,Positive,=,10230.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1466479611463769
VVVGAVGVGK,Positive-High,=,6954.0,nM,HLA-A*11:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.1823240661673129
YLVVGAAGV,Positive,=,16410.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10297180506290493
YLVVGACGV,Positive,=,26090.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.060118690899308214
YLVVGADGV,Positive,=,13420.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.12156227598302373
YLVVGARGV,Positive,=,15600.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10765027346733093
YLVVGASGV,Positive,=,21170.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07943211937343453
YLVVGAVGV,Positive,=,22950.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07197051995451631
YLVVVGAAGV,Positive,=,27740.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.05445098550589855
YLVVVGADGV,Positive-High,=,5683.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.2009785862475908
YLVVVGASGV,Positive,=,10650.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.14292927938282607
YLVVVGAVGV,Positive,=,15470.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10842369501540217
YVVVGAVGV,Positive,=,28260.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.05273450279419134
EAAGIGILTV,Positive,,22500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.07380074482379229
SLLMWITQC,Positive,,4450.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.22358303891823672
EAAGIGILTVI,Positive,,30700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),11,0.04508043862024291
ELAGIGILTV,Positive,,2480.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2776179295262677
EMAGIGILTV,Positive,,3600.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.24317403654722725
EIAGIGILTV,Positive,,3350.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2498260674607251
EVAGIGILTV,Positive,,4210.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2287071225201845
ELAGIGILTL,Positive,,4170.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2295894522345869
ELAGIGILTA,Positive,,5610.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.202173485296401
ELAGIGILTI,Positive,,2930.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2622069055229073
ELAGIGILTM,Positive,,36800.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.028330077770162613
EMAGIGILTL,Positive,,4380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.22504844526696374
EMAGIGILTA,Positive,,3620.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2426619945968299
EMAGIGILTI,Positive,,1790.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.30775190563500243
EMAGIGILTM,Positive,,37500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.026588536741671498
SLLMWITQA,Positive,,1090.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3535973851423163
SLLMWITQL,Positive,,1970.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2988960935861278
SLLMWITQV,Positive,,1190.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3454848703961633
SLLMWITQM,Positive,,2380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2814218958748952
SLLMWITQI,Positive,,1360.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.33314345367629183
SALMWITQA,Positive,,2280.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2853891716904157
SALMWITQL,Positive,,1990.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2979625166013703
SALMWITQV,Positive,,1700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31251978233584243
SALMWITQM,Positive,,11400.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1366395513074301
SALMWITQI,Positive,,2030.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2961231855361516
SMLMWITQA,Positive,,950.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3663029126508308
SMLMWITQL,Positive,,1340.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3345127133224426
SMLMWITQV,Positive,,1010.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3606425725190039
SMLMWITQM,Positive,,1570.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31987230191718885
SMLMWITQI,Positive,,710.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3932163120666763
SILMWITQA,Positive,,1920.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3012721456672733
SILMWITQL,Positive,,5420.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.20535792246113427
SILMWITQV,Positive,,1060.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3561768084339461
SILMWITQM,Positive,,3100.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2569942581858182
SILMWITQI,Positive,,2700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.26976257328889863
GILGFVFTL,Positive,,1020.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3597319904179632
EPRSPSHSM,Positive,=,27.0,nM,HLA-B*07:02,I,Literature,2023,Neoantigen-specific stem cell memory-like CD4&lt;sup&gt;+&lt;/sup&gt; T cells mediate CD8&lt;sup&gt;+&lt;/sup&gt; T cell-dependent immunotherapy of MHC class II-negative solid tumors.,purified MHC/direct/fluorescence,dissociation constant KD (~EC50),Homo sapiens (human),9,0.6953877630974059
LPASPAHQL,Positive,=,54.3,nM,HLA-B*07:02,I,Literature,2023,Neoantigen-specific stem cell memory-like CD4&lt;sup&gt;+&lt;/sup&gt; T cells mediate CD8&lt;sup&gt;+&lt;/sup&gt; T cell-dependent immunotherapy of MHC class II-negative solid tumors.,purified MHC/direct/fluorescence,dissociation constant KD (~EC50),Homo sapiens (human),9,0.6308127466257405
CWNVEQARF,Positive-High,,1925.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3010317727472659
RVAVILNEF,Positive-High,,2530.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.27577309111665826
LLAAPSAMA,Positive-Intermediate,,37120.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.02752987073120794
AAVTSQFPV,Positive-Intermediate,,27710.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.054550992731865366
LMAVEEREV,Positive-Intermediate,,34110.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.03534567889885698
GLMKGGANL,Positive-Intermediate,,16990.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.09976157009608601
KYISTSLPV,Positive-High,,7135.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.17994922847030093
IWEQLASRF,Positive-High,,6405.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1899247855235927
FFNKGGSVF,Positive-Intermediate,,13260.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.12267081503720212
LMKGGANLF,Positive-Intermediate,,26720.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05791344704933155
MLREQLDQV,Positive-Intermediate,,13870.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.11851396002716652
TLHGFVNHI,Positive-Intermediate,,10650.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.14292927938282607
RILSCLSDL,Positive-Intermediate,,29320.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04933124453934112
GLLHKVKEL,Positive-Intermediate,,30140.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.046781902449804624
ALLVVSREL,Positive-High,,5522.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2036347542439748
WLAKTRVFL,Positive-High,,5871.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19797060272782152
ILCKDLSTV,Positive-High,,9327.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15518890882475578
FLTDVACRV,Positive-High,,5380.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.20604254289263926
AVLERYLEL,Positive-High,,5962.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1965490377225576
MQSLHFAFL,Positive-Intermediate,,47660.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.004429899809186511
ALEAVRIEL,Positive-High,,5843.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19841244297482874
TLHDIWPEI,Positive-High,,9314.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15531781859978788
LFTKLHPAF,Positive-Intermediate,,19600.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0865538474610913
SYYMPQLFW,Positive-Intermediate,,27770.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.05435108637639618
EMQSLHFAF,Positive-High,,4845.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2157230673985694
KYSDVIKVL,Positive-High,,1376.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3320624666675245
DYPGQGFSF,Positive-High,,5841.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.19844408396645807
RFTLSVPGF,Positive-High,,1597.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3182963685270169
VYSFLCKTI,Positive-High,,606.9,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.40771762004815537
CIVYLSLSR,Positive-Intermediate,,39860.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.02094772043250337
GLYDVQLTI,Positive-Intermediate,,31720.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04205960572382483
ALLSNDNAL,Positive-High,,8692.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1617057112487147
LLPMSLHWFI,Positive-Intermediate,,38820.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.023391184277033128
LLFAKFSFLI,Positive-Intermediate,,19150.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.08870055047101177
RQLLFSLLAV,Positive-Intermediate,,24610.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.06551614297370212
SLNVDTAFPL,Positive-Intermediate,,45060.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.009614621269452228
TLAGHVYEYI,Positive-Intermediate,,48080.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.003618994231851636
KLIASILYQA,Positive-Intermediate,,16220.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10404815395921384
FLIHSSTGLI,Positive-Intermediate,,39570.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.02162260111816749
QYDPVAALF,Positive-High,,707.4,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.39355538493559705
GILGFVFTL,Positive-High,,7048.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.18108311143651634
ILRGSVAHK,Positive-High,,9460.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15388029020551264
YLQPRTFLL,Positive,,75.0,nM,HLA-A*02:01,I,Literature,2023,Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.,binding assay,dissociation constant KD,Homo sapiens (human),9,0.6009633469331641
ILDTAGKEEY,Positive,,260.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4860632551937173
ILDTAGLEEY,Positive,,329.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4643090090749232
ILDTAGHEEY,Positive,,239.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4938469709843969
ILDTAGREEY,Positive,,246.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4911788956096505
ILDTAGQEEY,Positive,,278.0,nM,HLA-A*01:01,I,Literature,2023,Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),10,0.4798764849184373
